IPP Bureau
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
By IPP Bureau - March 21, 2022
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Govt to deploy Truenat platform for TB screening across India
By IPP Bureau - March 19, 2022
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug
By IPP Bureau - March 19, 2022
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine
By IPP Bureau - March 19, 2022
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Manipal Hospitals deploys wearable technology to monitor post-surgery care
By IPP Bureau - March 19, 2022
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
USFDA approves Opdualag to treat metastatic melanoma
By IPP Bureau - March 19, 2022
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Tata Elxsi has unveiled TEngage, a digital health platform
By IPP Bureau - March 19, 2022
In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check
USFDA approves Marinus’ treatment for genetic disorder
By IPP Bureau - March 19, 2022
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
Aesculap launches new sterile container system
By IPP Bureau - March 19, 2022
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
.jpg "Thirty five generic manufacturers sign agreements with MPP for Paxlovid")
Thirty five generic manufacturers sign agreements with MPP for Paxlovid
By IPP Bureau - March 18, 2022
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
AstraZeneca launches global R&D post-doctoral challenge
By IPP Bureau - March 18, 2022
Successful proposals will secure fully funded postdoctoral research positions
Merck discontinues KEYLYNK-101 trial to treat prostate cancer
By IPP Bureau - March 18, 2022
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Health Canada authorizes Moderna's COVID-19 vaccine in children (6-11 Years)
By IPP Bureau - March 18, 2022
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
11-year-old Oman girl undergoes gastro trichobezoar surgery
By IPP Bureau - March 18, 2022
Doctors at Yashoda Hospitals Hyderabad perform rare operation
Sanofi moves forward with EUROAPI listing on Euronext Paris
By IPP Bureau - March 18, 2022
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
